Myomo (MYO) Stock Analysis & Winston Score

Myomo makes powered arm braces for people who have lost the ability to move their arms due to strokes, nerve damage, or other injuries. Its main product is the MyoPro, a motorized brace that reads faint electrical signals from a patient's muscles and uses them to help move the arm. The company sells to patients, hospitals, and rehabilitation clinics, mostly in the United States. Myomo earns revenue by selling MyoPro devices, which can cost tens of thousands of dollars each, with payment often coming through insurance or government programs like Medicare and Medicaid. The company is small, with a market cap under $100 million, and its competitive edge comes from its patented muscle-signal technology, which few rivals can replicate. The biggest risk is reimbursement — if insurers limit or deny coverage for the MyoPro, it becomes very hard for patients to afford the device, which would directly hurt sales growth.